Bio Rad Laboratories Stock Cash And Equivalents
| BIO-B Stock | USD 336.00 3.36 0.99% |
Bio Rad Laboratories fundamentals help investors to digest information that contributes to Bio Rad's financial success or failures. It also enables traders to predict the movement of Bio Stock. The fundamental analysis module provides a way to measure Bio Rad's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bio Rad stock.
Bio | Cash And Equivalents |
Bio Rad Laboratories Company Cash And Equivalents Analysis
Bio Rad's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Bio Rad Cash And Equivalents | 858.99 M |
Most of Bio Rad's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bio Rad Laboratories is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Bio Cash And Equivalents Driver Correlations
Understanding the fundamental principles of building solid financial models for Bio Rad is extremely important. It helps to project a fair market value of Bio Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since Bio Rad's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bio Rad's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bio Rad's interrelated accounts and indicators.
Click cells to compare fundamentals
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
CompetitionBio Cash And Cash Equivalents Changes
Cash And Cash Equivalents Changes |
|
In accordance with the recently published financial statements, Bio Rad Laboratories has 858.99 M in Cash And Equivalents. This is 4.64% higher than that of the Health Care Equipment & Supplies sector and 100.54% higher than that of the Health Care industry. The cash and equivalents for all United States stocks is 68.21% higher than that of the company.
Bio Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bio Rad's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bio Rad could also be used in its relative valuation, which is a method of valuing Bio Rad by comparing valuation metrics of similar companies.Bio Rad is currently under evaluation in cash and equivalents category among its peers.
Bio Fundamentals
| Return On Equity | -0.0979 | ||||
| Return On Asset | 0.0186 | ||||
| Profit Margin | (0.30) % | ||||
| Operating Margin | 0.1 % | ||||
| Current Valuation | 9.28 B | ||||
| Shares Outstanding | 5.07 M | ||||
| Shares Owned By Insiders | 97.96 % | ||||
| Shares Owned By Institutions | 0.08 % | ||||
| Number Of Shares Shorted | 3 | ||||
| Price To Earning | 17.05 X | ||||
| Price To Book | 1.26 X | ||||
| Price To Sales | 0.66 X | ||||
| Revenue | 2.67 B | ||||
| Gross Profit | 1.57 B | ||||
| EBITDA | (608.26 M) | ||||
| Net Income | (637.32 M) | ||||
| Cash And Equivalents | 858.99 M | ||||
| Cash Per Share | 28.81 X | ||||
| Total Debt | 1.41 B | ||||
| Debt To Equity | 13.90 % | ||||
| Current Ratio | 4.57 X | ||||
| Book Value Per Share | 267.46 X | ||||
| Cash Flow From Operations | 374.94 M | ||||
| Short Ratio | 0.20 X | ||||
| Earnings Per Share | (28.09) X | ||||
| Price To Earnings To Growth | 1.21 X | ||||
| Number Of Employees | 7.7 K | ||||
| Beta | 0.94 | ||||
| Market Capitalization | 1.71 B | ||||
| Total Asset | 12.3 B | ||||
| Retained Earnings | 9.26 B | ||||
| Working Capital | 2.53 B | ||||
| Net Asset | 12.3 B |
About Bio Rad Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bio Rad Laboratories's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bio Rad using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bio Rad Laboratories based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Bio Rad Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Rad's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Rad Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Rad Laboratories Stock:Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.